22310S000 Bicalutamide Clinical Pediatric Review

Total Page:16

File Type:pdf, Size:1020Kb

22310S000 Bicalutamide Clinical Pediatric Review CLINICAL REVIEW Application Type NDA Submission Number 22-310 Submission Code S-001 Letter Date June 25, 2008 Stamp Date June 25, 2008 PDUFA Goal Date December 25, 2008 Reviewer Name Dragos Roman Review Completion Date December 15, 2008 Established Name Bicalutamide (Proposed) Trade Name Casodex Therapeutic Class Antiandrogen Applicant AstraZeneca Pharmaceuticals Priority Designation P Formulation oral Dosing Regimen Indication treatment of gonadotropin- independent precocious puberty in familial male-limited precocious puberty (testotoxicosis) Intended Population boys with precocious puberty due to testotoxicosis Clinical Review {Dragos Roman} {NDA 22-310/S-001} {Casodex (bicalutamide)} Table of Contents 1 EXECUTIVE SUMMARY .....................................................................................................................................5 1.1 RECOMMENDATION ON REGULATORY ACTION ...................................................................................................5 1.2 RECOMMENDATION ON POSTMARKETING ACTIONS ............................................................................................5 1.2.1 Risk Management Activity.........................................................................................................................5 1.2.2 Required Phase 4 Commitments ................................................................................................................5 1.2.3 Other Phase 4 Requests..............................................................................................................................5 1.3 SUMMARY OF CLINICAL FINDINGS......................................................................................................................5 1.3.1 Brief Overview of Clinical Program ..........................................................................................................5 1.3.2 Efficacy ......................................................................................................................................................6 1.3.3 Safety .........................................................................................................................................................7 1.3.4 Dosing Regimen and Administration.........................................................................................................8 1.3.5 Drug-Drug Interactions ..............................................................................................................................8 1.3.6 Special Populations ....................................................................................................................................8 2 INTRODUCTION AND BACKGROUND............................................................................................................9 2.1 PRODUCT INFORMATION .....................................................................................................................................9 2.2 CURRENTLY AVAILABLE TREATMENT FOR INDICATIONS....................................................................................9 2.3 AVAILABILITY OF PROPOSED ACTIVE INGREDIENT IN THE UNITED STATES......................................................10 2.4 IMPORTANT ISSUES WITH PHARMACOLOGICALLY RELATED PRODUCTS ..........................................................10 2.5 PRESUBMISSION REGULATORY ACTIVITY .........................................................................................................11 2.6 OTHER RELEVANT BACKGROUND INFORMATION .............................................................................................11 3 SIGNIFICANT FINDINGS FROM OTHER REVIEW DISCIPLINES..........................................................11 3.1 CMC (AND PRODUCT MICROBIOLOGY, IF APPLICABLE) ...................................................................................11 3.2 ANIMAL PHARMACOLOGY/TOXICOLOGY ..........................................................................................................11 4 DATA SOURCES, REVIEW STRATEGY, AND DATA INTEGRITY ..........................................................11 4.1 SOURCES OF CLINICAL DATA............................................................................................................................11 4.2 TABLES OF CLINICAL STUDIES ..........................................................................................................................12 4.3 REVIEW STRATEGY ...........................................................................................................................................12 4.4 DATA QUALITY AND INTEGRITY .......................................................................................................................12 4.5 COMPLIANCE WITH GOOD CLINICAL PRACTICES ..............................................................................................12 4.6 FINANCIAL DISCLOSURES .................................................................................................................................13 5 CLINICAL PHARMACOLOGY.........................................................................................................................13 5.1 PHARMACOKINETICS.........................................................................................................................................13 5.2 PHARMACODYNAMICS ......................................................................................................................................15 5.3 EXPOSURE-RESPONSE RELATIONSHIPS .............................................................................................................16 6 INTEGRATED REVIEW OF EFFICACY.........................................................................................................16 6.1 INDICATION.......................................................................................................................................................16 6.1.1 Methods....................................................................................................................................................17 6.1.2 General Discussion of Endpoints .............................................................................................................17 6.1.3 Study Design ............................................................................................................................................17 6.1.4 Efficacy Findings .....................................................................................................................................23 6.1.5 Clinical Microbiology ..............................................................................................................................32 6.1.6 Efficacy Conclusions ...............................................................................................................................33 7 INTEGRATED REVIEW OF SAFETY..............................................................................................................34 7.1 METHODS AND FINDINGS ..................................................................................................................................34 7.1.1 Deaths ......................................................................................................................................................34 2 Clinical Review {Dragos Roman} {NDA 22-310/S-001} {Casodex (bicalutamide)} 7.1.2 Other Serious Adverse Events..................................................................................................................34 7.1.3 Dropouts and Other Significant Adverse Events......................................................................................34 7.1.4 Other Search Strategies ............................................................................................................................34 7.1.5 Common Adverse Events.........................................................................................................................35 7.1.6 Less Common Adverse Events ................................................................................................................38 7.1.7 Laboratory Findings .................................................................................................................................38 7.1.8 Vital Signs.................................................................................................................................................46 7.1.9 Electrocardiograms (ECGs) .....................................................................................................................46 7.1.10 Immunogenicity .....................................................................................................................................47 7.1.11 Human Carcinogenicity .........................................................................................................................47 7.1.12 Special Safety Studies ............................................................................................................................47 7.1.13 Withdrawal Phenomena and/or Abuse Potential....................................................................................47 7.1.14 Human Reproduction and Pregnancy Data ............................................................................................47 7.1.15 Assessment of Effect on Growth............................................................................................................47
Recommended publications
  • Prnu-BICALUTAMIDE
    PRODUCT MONOGRAPH PrNU-BICALUTAMIDE Bicalutamide Tablets, 50 mg Non-Steroidal Antiandrogen NU-PHARM INC. DATE OF PREPARATION: 50 Mural Street, Units 1 & 2 October 16, 2009 Richmond Hill, Ontario L4B 1E4 Control#: 133521 Page 1 of 27 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION....................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 3 WARNINGS AND PRECAUTIONS....................................................................................... 4 ADVERSE REACTIONS......................................................................................................... 5 DRUG INTERACTIONS ......................................................................................................... 9 DOSAGE AND ADMINISTRATION ................................................................................... 10 OVERDOSAGE...................................................................................................................... 10 ACTION AND CLINICAL PHARMACOLOGY.................................................................. 10 STORAGE AND STABILITY............................................................................................... 11 DOSAGE FORMS, COMPOSITION AND PACKAGING
    [Show full text]
  • Context-Specific Efficacy of Apalutamide Therapy in Preclinical
    cancers Article Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer Marco A. De Velasco 1,2,* , Yurie Kura 1,2, Naomi Ando 1, Noriko Sako 1, Eri Banno 1, Kazutoshi Fujita 1, Masahiro Nozawa 1, Kazuhiro Yoshimura 1 , Kazuko Sakai 2, Kazuhiro Yoshikawa 3, Kazuto Nishio 2 and Hirotsugu Uemura 1,* 1 Department of Urology Kindai, University Faculty of Medicine, Osaka-Sayama 589-8511, Japan; [email protected] (Y.K.); [email protected] (N.A.); [email protected] (N.S.); [email protected] (E.B.); [email protected] (K.F.); [email protected] (M.N.); [email protected] (K.Y.) 2 Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama 589-8511, Japan; [email protected] (K.S.); [email protected] (K.N.) 3 Research Creation Support Center, Aichi Medical University, Nagakute 480-1195, Japan; [email protected] * Correspondence: [email protected] (M.A.D.V.); [email protected] (H.U.) Simple Summary: Next-generation antiandrogens have transformed the therapeutic landscape for castration-resistant prostate cancer. Their utility in other indications, such as high-risk castration- sensitive cancers and as combination therapy, are being investigated. Our aim was to profile the in vivo antitumor activity of apalutamide in phenotypically distinct mouse models of Pten-deficient castration-naïve and castration-resistant prostate cancer, using both early- and late-stage disease Citation: De Velasco, M.A.; Kura, Y.; models, and to profile the molecular responses.
    [Show full text]
  • Download PDF File
    Ginekologia Polska 2019, vol. 90, no. 9, 520–526 Copyright © 2019 Via Medica ORIGINAL PAPER / GYNECologY ISSN 0017–0011 DOI: 10.5603/GP.2019.0091 Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality — a preliminary study Anna Fuchs, Aleksandra Matonog, Paulina Sieradzka, Joanna Pilarska, Aleksandra Hauzer, Iwona Czech, Agnieszka Drosdzol-Cop Department of Pregnancy Pathology, Department of Woman’s Health, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland ABSTRACT Objectives: Using anti-androgenic contraception is one of the methods of birth control. It also has a significant, non-con- traceptive impact on women’s body. These drugs can be used in various endocrinological disorders, because of their ability to reduce the level of male hormones. The aim of our study is to establish a correlation between taking different types of anti-androgenic drugs and intensity of hirsutism, acne, menstrual pain intensity and sexuality . Material and methods: 570 women in childbearing age that had been using oral contraception for at least three months took part in our research. We examined women and asked them about quality of life, health, direct causes and effects of that treatment, intensity of acne and menstrual pain before and after. Our research group has been divided according to the type of gestagen contained in the contraceptive pill: dienogest, cyproterone, chlormadynone and drospirenone. Ad- ditionally, the control group consisted of women taking oral contraceptives without antiandrogenic component. Results: The mean age of the studied group was 23 years ± 3.23. 225 of 570 women complained of hirsutism.
    [Show full text]
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
    pharmaceuticals Review COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis 1,* , Kacper Lechowicz 1 , Sylwester Drozd˙ zal˙ 2 , Paulina Nied´zwiedzka-Rystwej 3 , Tomasz K. Wojdacz 4, Ewelina Grywalska 5 , Jowita Biernawska 6, Magda Wi´sniewska 7 and Miłosz Parczewski 8 1 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; [email protected] 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 3 Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland; [email protected] 4 Independent Clinical Epigenetics Laboratory, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] 5 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 6 Department of Anesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] 7 Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 8 Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; [email protected] * Correspondence: katarzyna.kotfi[email protected]; Tel.: +48-91-466-11-44 Abstract: In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared Citation: Kotfis, K.; Lechowicz, K.; a global pandemic by the World Health Organization (WHO). The clinical course of the disease is Drozd˙ zal,˙ S.; Nied´zwiedzka-Rystwej, unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to P.; Wojdacz, T.K.; Grywalska, E.; acute respiratory distress syndrome (ARDS).
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration- Resistant Prostate Cancer Anna C
    Published OnlineFirst January 3, 2019; DOI: 10.1158/1078-0432.CCR-18-1589 Clinical Trials: Targeted Therapy Clinical Cancer Research Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration- Resistant Prostate Cancer Anna C. Ferrari1, Joshi J. Alumkal2, Mark N. Stein3, Mary-Ellen Taplin4, James Babb5, Ethan S. Barnett6, Alejandro Gomez-Pinillos5, Xiaomei Liu5, Dirk Moore6, Robert DiPaola7, and Tomasz M. Beer2 Abstract Purpose: This study assesses the action of panobino- Results: In the model, panobinostat/bicalutamide demon- stat, a histone deacetylase inhibitor (HDACI), in restor- strated synergistic antitumor effect while reducing AR activity. ing sensitivity to bicalutamide in a castration-resistant The dose-limiting toxicity was not reached. The probabilities of prostate cancer (CRPC) model and the efficacy and safety remaining rPF were 47.5% in the A arm and 38.5% in the B arm, of the panobinostat/bicalutamide combination in CRPC exceeding the protocol-specified threshold of 35%. The A arm patients resistant to second-line antiandrogen therapy but not the B arm exceeded expectations for times (medians) to (2ndLAARx). rP (33.9 and 10 weeks), and from PSA progression to rP (24 and Patients and Methods: The CWR22PC xenograft and 5.9 weeks). A arm/B arm events included: adverse events (AE), isogenic cell line were tested for drug interactions on 62%/19%; treatment stopped for AEs, 27.5%/11.5%; dose tumor cell growth and on the androgen receptor (AR), reduction required, 41%/4%. The principal A-arm grade 3 AR-splice variant7, and AR targets. A phase I trial had a AEs were thrombocytopenia (31%) and fatigue (14%).
    [Show full text]
  • How to Select Pharmacologic Treatments to Manage Recidivism Risk in Sex Off Enders
    How to select pharmacologic treatments to manage recidivism risk in sex off enders Consider patient factors when choosing off -label hormonal and nonhormonal agents ® Dowden Healthex offenders Media traditionally are managed by the criminal justice system, but psychiatrists are fre- Squently called on to assess and treat these indi- CopyrightFor personalviduals. use Part only of the reason is the overlap of paraphilias (disorders of sexual preference) and sexual offending. Many sexual offenders do not meet DSM criteria for paraphilias,1 however, and individuals with paraphil- ias do not necessarily commit offenses or come into contact with the legal system. As clinicians, we may need to assess and treat a wide range of sexual issues, from persons with paraphilias who are self-referred and have no legal involvement, to recurrent sexual offenders who are at a high risk of repeat offending. Successfully managing sex offenders includes psychological and pharmacologic interven- 2009 © CORBIS / TIM PANNELL 2009 © CORBIS / tions and possibly incarceration and post-incarceration Bradley D. Booth, MD surveillance. This article focuses on pharmacologic in- Assistant professor terventions for male sexual offenders. Department of psychiatry Director of education Integrated Forensics Program University of Ottawa Reducing sexual drive Ottawa, ON, Canada Sex offending likely is the result of a complex inter- play of environment and psychological and biologic factors. The biology of sexual function provides nu- merous targets for pharmacologic intervention, in- cluding:2 • endocrine factors, such as testosterone • neurotransmitters, such as serotonin. The use of pharmacologic treatments for sex of- fenders is off-label, and evidence is limited. In general, Current Psychiatry 60 October 2009 pharmacologic treatments are geared toward reducing For mass reproduction, content licensing and permissions contact Dowden Health Media.
    [Show full text]
  • Feminizing Hormone Therapy
    FEMINIZING HORMONE THERAPY Julie Thompson, PA-C Medical Director of Trans Health, Fenway Health April 2020 fenwayhealth.org GOALS AND OBJECTIVES 1. Review process of initiating hormone therapy through the informed consent model 2. Provide an overview of feminizing hormone therapy 3. Review realistic expectations and benefits of hormone therapy vs their associated risks 4. Discuss recommendations for monitoring fenwayhealth.org PROTOCOLS AND STANDARDS OF CARE fenwayhealth.org WPATH STANDARDS OF CARE, 2011 The criteria for hormone therapy are as follows: 1. Well-documented, persistent (at least 6mo) gender dysphoria 2. Capacity to make a fully informed decision and to consent for treatment 3. Age of majority in a given country 4. If significant medical or mental health concerns are present, they must be reasonably well controlled fenwayhealth.org INFORMED CONSENT MODEL ▪ Requires healthcare provider to ▪ Effectively communicate benefits, risks and alternatives of treatment to patient ▪ Assess that the patient is able to understand and consent to the treatment ▪ Informed consent model does not preclude mental health care! ▪ Recognizes that prescribing decision ultimately rests with clinical judgment of provider working together with the patient ▪ Recognizes patient autonomy and empowers self-agency ▪ Decreases barriers to medically necessary care fenwayhealth.org INITIAL VISITS ▪ Review history of gender experience and patient’s goals ▪ Document prior hormone use ▪ Assess appropriateness for gender affirming medical treatment ▪ WPATH criteria
    [Show full text]
  • WO 2018/111890 Al 21 June 2018 (21.06.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/111890 Al 21 June 2018 (21.06.2018) W !P O PCT (51) International Patent Classification: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, C07K 16/28 (2006.01) A61K 31/4166 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 59/595 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/US20 17/065841 Declarations under Rule 4.17: (22) International Filing Date: — as to applicant's entitlement to apply for and be granted a 12 December 2017 (12.12.2017) patent (Rule 4.1 7(H)) — as to the applicant's entitlement to claim the priority of the (25) Filing Language: English earlier application (Rule 4.17(Hi)) (26) Publication Langi English — of inventorship (Rule 4.1 7(iv)) (30) Priority Data: Published: 62/433,158 12 December 2016 (12.12.2016) US — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (71) Applicant (for all designated States except AL, AT, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, P T RO, RS, SE, SI, SK, SM, TR): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).
    [Show full text]
  • Androgen Receptor Is Targeted to Distinct Subcellular Compartments in Response to Different Therapeutic Antiandrogens
    7392 Vol. 10, 7392–7401, November 1, 2004 Clinical Cancer Research Androgen Receptor Is Targeted to Distinct Subcellular Compartments in Response to Different Therapeutic Antiandrogens Hayley C. Whitaker,1 Sarah Hanrahan,3 informed sequential treatment regime may benefit prostate Nick Totty,3 Simon C. Gamble,1 cancer patients. The observed subnuclear and subcytoplas- Jonathan Waxman,1 Andrew C. B. Cato,4 mic associations of the AR suggest new areas of study to 2 1 investigate the role of the AR in the response and resistance Helen C. Hurst, and Charlotte L. Bevan of prostate cancer to antiandrogen therapy. 1Prostate Cancer Research Group and 2Cancer Research UK Molecular Oncology Unit, Department of Cancer Medicine, Faculty of Medicine, Imperial College London, London, United Kingdom; INTRODUCTION 3Protein Analysis, Cancer Research UK, London Research Institute, Prostate cancer is the most commonly diagnosed male London, United Kingdom; and 4Forschungszentrum Karlsruhe, cancer in the United States and the second leading cause of male Institute of Toxicology and Genetics, Karlsruhe, Germany cancer death (1). Prostate growth is initially androgen depend- ent; thus, treatment involves reducing circulating androgen lev- ABSTRACT els using leuteinizing hormone-releasing hormone analogs and opposing androgen action using antiandrogens. Little is known Purpose: Antiandrogens are routinely used in the treat- about how antiandrogens elicit their effects, although they act at ment of prostate cancer. Although they are known to pre- the level of the androgen receptor (AR), which mediates the vent activation of the androgen receptor (AR), little is effects of all androgens including the major circulating androgen known about the mechanisms involved. This report repre- testosterone and the more potent dihydrotestosterone (DHT).
    [Show full text]
  • Minutes of PRAC Meeting on 09-12 July 2018
    6 September 2018 EMA/PRAC/576790/2018 Inspections, Human Medicines Pharmacovigilance and Committees Division Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of the meeting on 09-12 July 2018 Chair: June Raine – Vice-Chair: Almath Spooner Health and safety information In accordance with the Agency’s health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scope listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, the minutes are a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1). 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018.
    [Show full text]